Literature DB >> 30228932

TumGrowth: An open-access web tool for the statistical analysis of tumor growth curves.

David P Enot1,2,3,4,5,6, Erika Vacchelli1,2,3,4,5,6,7,8, Nicolas Jacquelot9,10,11,7,8, Laurence Zitvogel9,10,11,12, Guido Kroemer1,2,3,4,5,6,13,14.   

Abstract

The analysis of tumor growth curves is standard practice in experimental oncology including tumor immunology. In experimental oncology, cancer cells are inoculated into rodents (mostly mice) and their growth is monitored by measuring tumor diameter, surface or volume over time as a function of distinct treatments. Then, different groups of tumors/treatments are compared among each other for their evolution and possible responses to treatment. The R package TumGrowth has been created as a software tool allowing to carry out a series of statistical comparisons across or between groups of tumor growth curves obtained in a standard laboratory, for experimenters with limited knowledge in statistics. TumGrowth is freely available online at https://kroemerlab.shinyapps.io/TumGrowth/ and can be downloaded into any computer. It offers an exhaustive panoply of tools to visualize and analyze complex data sets including longitudinal, cross-sectional and time-to-endpoint measurements.

Entities:  

Keywords:  mice; statistical analyses; survival; tumor growth

Year:  2018        PMID: 30228932      PMCID: PMC6140814          DOI: 10.1080/2162402X.2018.1462431

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


Preclinical models of oncogenesis, tumor progression and treatment responses are essential for experimental cancer research. In a typical experiment, rodents (usually mice or rats) are inoculated subcutaneously with transplantable tumors that are either isogeneic (if the recipient is immunocompetent) or can be histo-incompatible or even xenogeneic (if the recipient is immunodeficient). Alternatively, cancer cells can be injected orthotopically, into the organ from which they originate, and tumor monitoring then requires image technologies based on fluorescence of luminescence signals (if the tumor has been transduced with appropriate biosensors) or radiological methods (such as micro-computer tomographic scans). Experimental cancers may also be induced by the regular administration of chemical carcinogens or genetic manipulations aiming at the activation of oncogenes. The scope of most experiments is to evaluate the capacity of treatments to prevent, reduce or abolish tumor growth, meaning that drugs or appropriate vehicle controls are administered to the animals and the growth of the tumor is recorded over time as a function of the treatment. Independently of the exact way how tumors are generated, treated and monitored, in a typical experimental setup, multiple measurements of tumor diameter, surface or volume are monitored, by calipers, in several groups of rodents at different time points. The analysis of such data, which often are non-linear in nature (due to the effects of treatments and the impact of increased or relaxed immunosurveillance) and frequently are afflicted by major inter-individual variations within the same treatment group, often trespasses the statistical competence of the experimenter, yielding suboptimal analyses or requiring the involvement of a professional biostatistician. Driven by these premises, we decided to create an annotated software package that can be used by experimenters without programming knowledge to take advantage of the functionalities of the R environment coupled to the Shiny framework. The software entitled TumGrowth (see Fig. 1 for an overview) allows the user to upload data generated in conventional spreadsheet software, to verify the overall experimental design and data integrity, to visualize the entire experiments or selected groups alone or en masse, and then to perform three alternative, yet complementary statistical analyses, depending on three types of questions:
Figure 1.

Overall workflow of the TumGrowth software. After data upload, the user verifies the integrity of the data file, visualizes the experimental outcome while allowing the investigator to choose among several possibilities, then performs several distinct statistical comparisons (longitudinal, cross-sectional, time-to-endpoint) and finally generates publication quality Figs., as well as detailed statistical reports.

Does a treatment affect the trajectory of tumor growth? For this, longitudinal analysis can be performed either on the entire tumor growth curve or on segments thereof, and the effects of the overall experimental intervention (over all group) can be analyzed statistically in the same way as groups can be subjected to pairwise comparisons. Does a treatment affect tumor size at a given time point chosen by the experimenter? For this, the visualization program facilitates the choice of the time point, and the software package yields statistical comparisons across and between groups. Does a variation in experimental conditions impact on the appearance (or disappearance) of tumors, the overall survival of animals or their survival up to a critical maximum tumor size? Overall workflow of the TumGrowth software. After data upload, the user verifies the integrity of the data file, visualizes the experimental outcome while allowing the investigator to choose among several possibilities, then performs several distinct statistical comparisons (longitudinal, cross-sectional, time-to-endpoint) and finally generates publication quality Figs., as well as detailed statistical reports. TumGrowth application not only allows for exporting new generated graphs, for the inclusion in laboratory notebooks and scientific articles, but also it generates a full set of Materials and Methods (by automatically creating statistical reports that comprise experimental design, modeling settings, description of the statistical tests used for the calculation of p-value as well as diagnostic plots) to explain how each graph and each statistical comparison has been calculated. TumGrowth is freely available online at https://kroemerlab.shinyapps.io/TumGrowth/ (utilization limited to 25 hours per month) and can be downloaded into any computer to be used offline as well (without limitations to its use). As a free interactive web tool, TumGrowth should profit to technicians, students, post-docs and established investigators working in the area of experimental oncology. Examples of its recent use include articles in Cancer Cell, Immunity, OncoImmunology and Science. We anticipate that its use will improve the statistical analyses of experimental tumor growth curves in an ever-expanding number of laboratories. In principle, this statistical package might also be used to analyze growth curves of mice subjected to obesogenic diets.

Materials and methods

Data input

Growth data of each individual tumor (usually as raw data resulting from the measurement of two or three dimensions of the tumor surface/volume) can be uploaded as a tab-separated text file (.txt). Such text files can be exported from any standard spreadsheet software (e.g. .xls or .xlsx) or even text files (e.g. .doc), which are widely used for the documentation of tumor growth experiment in experimental oncology laboratories.

Analyses performed by TumGrowth

The data are subjected to interactive visualization using several distinct submenus (Line charts section) of the program allowing the experimenter to understand the biological outcome of the experiment. Moreover, tumor growth data are subjected to three different types of statistical comparison, and each of the three submenus (Longitudinal analysis, Cross-sectional analysis, Survival analysis) designed for this purpose contain text annotations to guide the user. First, longitudinal analyses are performed over entire segments of the tumor growth curves that can be subjected to automatic analyses of breakpoints in the tumor growth characteristics and outlier detection on the basis of Bonferroni-corrected p-values calculated from the residuals (if required). In the next step, the tumor growth curves are subjected to type II ANOVA and pairwise comparisons across groups. The user can select the comparison of choice. Moreover, the software comprises a series of diagnostic plots, allowing the user to verify the adequacy of the statistical model that is applied. Second, cross-sectional analyses allow for the comparison of tumor dimensions at one single time point that is chosen by the user upon interactive visualization of different options. Such data sets can again be subjected to outlier detection on the basis of Bonferroni-corrected p-values calculated from the residuals (if required), followed by comparison of groups. The software then calculates p-values via the Wilcoxon rank sum test that can be adjusted by the Holm method. Third, time-to-endpoint data are visualized as Kaplan Meier plots and subjected to statistical comparisons by means of the Cox regression model, likelihood ratios, Wald and score tests. It is important to note that the program is flexible in specifying alternative censoring cut-offs (e.g. time of apparition of the tumor, maximum tumor size, survival of the animal, length of the experiment etc.). Estimation of hazard ratios is always possible, even in the absence of events, by means of the Firth correction.

Exporting results

Each graph can be exported as a .png or .svg file, knowing that .svg files are compatible with graphical software (such as Adobe Illustrator) that is widely used by the biomedical research community. Each of the statistical report can be exported as .doc, or .htlm or .pdf document. Such reports include plots of the transformed data, tables summarizing design and model specification, a description of the statistical methods used for intergroup comparisons, as well as diagnostic plots for statistical quality control.
  7 in total

1.  Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1.

Authors:  Erika Vacchelli; Yuting Ma; Elisa E Baracco; Antonella Sistigu; David P Enot; Federico Pietrocola; Heng Yang; Sandy Adjemian; Kariman Chaba; Michaela Semeraro; Michele Signore; Adele De Ninno; Valeria Lucarini; Francesca Peschiaroli; Luca Businaro; Annamaria Gerardino; Gwenola Manic; Thomas Ulas; Patrick Günther; Joachim L Schultze; Oliver Kepp; Gautier Stoll; Céline Lefebvre; Claire Mulot; Francesca Castoldi; Sylvie Rusakiewicz; Sylvain Ladoire; Lionel Apetoh; José Manuel Bravo-San Pedro; Monica Lucattelli; Cécile Delarasse; Valérie Boige; Michel Ducreux; Suzette Delaloge; Christophe Borg; Fabrice André; Giovanna Schiavoni; Ilio Vitale; Pierre Laurent-Puig; Fabrizio Mattei; Laurence Zitvogel; Guido Kroemer
Journal:  Science       Date:  2015-10-29       Impact factor: 47.728

2.  Caloric Restriction Mimetics Enhance Anticancer Immunosurveillance.

Authors:  Federico Pietrocola; Jonathan Pol; Erika Vacchelli; Shuan Rao; David P Enot; Elisa E Baracco; Sarah Levesque; Francesca Castoldi; Nicolas Jacquelot; Takahiro Yamazaki; Laura Senovilla; Guillermo Marino; Fernando Aranda; Sylvère Durand; Valentina Sica; Alexis Chery; Sylvie Lachkar; Verena Sigl; Norma Bloy; Aitziber Buque; Simonetta Falzoni; Bernhard Ryffel; Lionel Apetoh; Francesco Di Virgilio; Frank Madeo; Maria Chiara Maiuri; Laurence Zitvogel; Beth Levine; Josef M Penninger; Guido Kroemer
Journal:  Cancer Cell       Date:  2016-07-11       Impact factor: 31.743

3.  Contribution of RIP3 and MLKL to immunogenic cell death signaling in cancer chemotherapy.

Authors:  Heng Yang; Yuting Ma; Guo Chen; Heng Zhou; Takahiro Yamazaki; Christophe Klein; Federico Pietrocola; Erika Vacchelli; Sylvie Souquere; Allan Sauvat; Laurence Zitvogel; Oliver Kepp; Guido Kroemer
Journal:  Oncoimmunology       Date:  2016-03-10       Impact factor: 8.110

4.  Inhibition of formyl peptide receptor 1 reduces the efficacy of anticancer chemotherapy against carcinogen-induced breast cancer.

Authors:  Elisa E Baracco; Federico Pietrocola; Aitziber Buqué; Norma Bloy; Laura Senovilla; Laurence Zitvogel; Erika Vacchelli; Guido Kroemer
Journal:  Oncoimmunology       Date:  2016-02-18       Impact factor: 8.110

5.  Enterococcus hirae and Barnesiella intestinihominis Facilitate Cyclophosphamide-Induced Therapeutic Immunomodulatory Effects.

Authors:  Romain Daillère; Marie Vétizou; Nadine Waldschmitt; Takahiro Yamazaki; Christophe Isnard; Vichnou Poirier-Colame; Connie P M Duong; Caroline Flament; Patricia Lepage; Maria Paula Roberti; Bertrand Routy; Nicolas Jacquelot; Lionel Apetoh; Sonia Becharef; Sylvie Rusakiewicz; Philippe Langella; Harry Sokol; Guido Kroemer; David Enot; Antoine Roux; Alexander Eggermont; Eric Tartour; Ludger Johannes; Paul-Louis Woerther; Elisabeth Chachaty; Jean-Charles Soria; Encouse Golden; Silvia Formenti; Magdalena Plebanski; Mutsa Madondo; Philip Rosenstiel; Didier Raoult; Vincent Cattoir; Ivo Gomperts Boneca; Mathias Chamaillard; Laurence Zitvogel
Journal:  Immunity       Date:  2016-10-04       Impact factor: 31.745

Review 6.  Mouse models in oncoimmunology.

Authors:  Laurence Zitvogel; Jonathan M Pitt; Romain Daillère; Mark J Smyth; Guido Kroemer
Journal:  Nat Rev Cancer       Date:  2016-09-30       Impact factor: 60.716

7.  Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota.

Authors:  Marie Vétizou; Jonathan M Pitt; Romain Daillère; Patricia Lepage; Nadine Waldschmitt; Caroline Flament; Sylvie Rusakiewicz; Bertrand Routy; Maria P Roberti; Connie P M Duong; Vichnou Poirier-Colame; Antoine Roux; Sonia Becharef; Silvia Formenti; Encouse Golden; Sascha Cording; Gerard Eberl; Andreas Schlitzer; Florent Ginhoux; Sridhar Mani; Takahiro Yamazaki; Nicolas Jacquelot; David P Enot; Marion Bérard; Jérôme Nigou; Paule Opolon; Alexander Eggermont; Paul-Louis Woerther; Elisabeth Chachaty; Nathalie Chaput; Caroline Robert; Christina Mateus; Guido Kroemer; Didier Raoult; Ivo Gomperts Boneca; Franck Carbonnel; Mathias Chamaillard; Laurence Zitvogel
Journal:  Science       Date:  2015-11-05       Impact factor: 47.728

  7 in total
  45 in total

1.  Lurbinectedin synergizes with immune checkpoint blockade to generate anticancer immunity.

Authors:  Wei Xie; Sabrina Forveille; Kristina Iribarren; Allan Sauvat; Laura Senovilla; Yan Wang; Juliette Humeau; Maria Perez-Lanzon; Heng Zhou; Juan F Martínez-Leal; Guido Kroemer; Oliver Kepp
Journal:  Oncoimmunology       Date:  2019-09-05       Impact factor: 8.110

2.  Chemical activation of SAT1 corrects diet-induced metabolic syndrome.

Authors:  Federico Pietrocola; Guido Kroemer; Francesca Castoldi; Mervi T Hyvönen; Sylvère Durand; Fanny Aprahamian; Allan Sauvat; Shoaib A Malik; Elisa Elena Baracco; Erika Vacchelli; Paule Opolon; Nicolas Signolle; Déborah Lefevre; Noelie Bossut; Tobias Eisenberg; Christopher Dammbrueck; Tobias Pendl; Margerie Kremer; Sylvie Lachkar; Claudia Einer; Bernhard Michalke; Hans Zischka; Frank Madeo; Tuomo A Keinänen; Maria Chiara Maiuri
Journal:  Cell Death Differ       Date:  2020-05-06       Impact factor: 15.828

3.  Chemotherapy-induced ileal crypt apoptosis and the ileal microbiome shape immunosurveillance and prognosis of proximal colon cancer.

Authors:  Maria Paula Roberti; Satoru Yonekura; Connie P M Duong; Marion Picard; Gladys Ferrere; Maryam Tidjani Alou; Conrad Rauber; Valerio Iebba; Christian H K Lehmann; Lukas Amon; Diana Dudziak; Lisa Derosa; Bertrand Routy; Caroline Flament; Corentin Richard; Romain Daillère; Aurélie Fluckiger; Isabelle Van Seuningen; Mathias Chamaillard; Audrey Vincent; Stephanie Kourula; Paule Opolon; Pierre Ly; Eugénie Pizzato; Sonia Becharef; Juliette Paillet; Christophe Klein; Florence Marliot; Filippo Pietrantonio; Stéphane Benoist; Jean-Yves Scoazec; Peggy Dartigues; Antoine Hollebecque; David Malka; Franck Pagès; Jérôme Galon; Ivo Gomperts Boneca; Patricia Lepage; Bernard Ryffel; Didier Raoult; Alexander Eggermont; Tom Vanden Berghe; François Ghiringhelli; Peter Vandenabeele; Guido Kroemer; Laurence Zitvogel
Journal:  Nat Med       Date:  2020-05-25       Impact factor: 53.440

4.  Contribution of annexin A1 to anticancer immunosurveillance.

Authors:  Elisa Elena Baracco; Gautier Stoll; Peter Van Endert; Laurence Zitvogel; Erika Vacchelli; Guido Kroemer
Journal:  Oncoimmunology       Date:  2019-08-14       Impact factor: 8.110

5.  T cell circuits that sense antigen density with an ultrasensitive threshold.

Authors:  Katelyn A Cabral; Olivia A Creasey; Rogelio A Hernandez-Lopez; Wei Yu; Maria Del Pilar Lopez Pazmino; Yurie Tonai; Arsenia De Guzman; Anna Mäkelä; Kalle Saksela; Zev J Gartner; Wendell A Lim
Journal:  Science       Date:  2021-02-25       Impact factor: 47.728

6.  Adoptive transfer of immature myeloid cells lacking NF-κB p50 (p50-IMC) impedes the growth of MHC-matched high-risk neuroblastoma.

Authors:  Cheng Cui; Theresa Barberi; Rahul Suresh; Alan D Friedman
Journal:  Mol Oncol       Date:  2021-05-02       Impact factor: 6.603

7.  A genotype-phenotype screening system using conditionally immortalized immature dendritic cells.

Authors:  Liwei Zhao; Peng Liu; Wei Xie; Shuai Zhang; Sebastian Thieme; Laurence Zitvogel; Guido Kroemer; Oliver Kepp
Journal:  STAR Protoc       Date:  2021-08-12

8.  Evaluation of a Platinum-Acridine Anticancer Agent and Its Liposomal Formulation in an in vivo Model of Lung Adenocarcinoma.

Authors:  Song Ding; Christopher L Hackett; Fang Liu; Ryan G Hackett; Ulrich Bierbach
Journal:  ChemMedChem       Date:  2020-10-22       Impact factor: 3.466

9.  IGF1 receptor inhibition amplifies the effects of cancer drugs by autophagy and immune-dependent mechanisms.

Authors:  Qi Wu; Ai-Ling Tian; Bei Li; Marion Leduc; Sabrina Forveille; Peter Hamley; Warren Galloway; Wei Xie; Peng Liu; Liwei Zhao; Shuai Zhang; Pan Hui; Frank Madeo; Yi Tu; Oliver Kepp; Guido Kroemer
Journal:  J Immunother Cancer       Date:  2021-06       Impact factor: 13.751

10.  Pharmacological inhibitors of anaplastic lymphoma kinase (ALK) induce immunogenic cell death through on-target effects.

Authors:  Adriana Petrazzuolo; Maria Perez-Lanzon; Isabelle Martins; Peng Liu; Oliver Kepp; Véronique Minard-Colin; Maria Chiara Maiuri; Guido Kroemer
Journal:  Cell Death Dis       Date:  2021-07-16       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.